Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cardiology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cardiology Other
    The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials - (BMJ)
    FDA Approves Dronedarone for Atrial Fibrillation or Atrial Flutter - (DGNews)
    Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease - (JAMA)
    Novel and conventional biomarkers for prediction of incident cardiovascular events in the community - (JAMA)
    Kidney function and risk of cardiovascular disease and mortality in women: a prospective cohort study - (BMJ)

    News archive

     Recent webcasts/CME - Cardiology Other
    • State of the Science in Managing the Treatment-Experienced Patient With HIV
    • What's New in Managing Treatment-Experienced Patients With HIV?
    • Applying Data to Practice: Case Vignettes
    • Rheumatoid Arthritis: The Heart of the Matter Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis
      Supraventricular Tachycardia in Children and Adolescents

      Webcasts/CME archive

       Recent cases - Cardiology Other
        Cardiogenic Shock Caused by Disulfiram
        Congenital Atresia of the Left Main Coronary Artery Associated With Patent Ductus Arteriosus and Aortic Regurgitation
        Pleural Effusion and Pulmonary Hypertension in a Patient With Parkinson Disease Treated With Cabergoline
        A Well-Circumscribed Density Along the Right Heart Border
        A Case of Massive Pulmonary Embolism with ST Elevation in Leads V1-4

        Cases archive
          




        my personal edition > cardiology other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Pravastatin Plays Significant Role in Preventing Progression of Coronary Atherosclerosis

        A DGReview of :"Preventing angiographic progression of coronary atherosclerosis with pravastatin"
        Journal of Atherosclerosis and Thrombosis

        03/28/2003
        By Veronica Rose


        Clinical efficacy of pravastatin might be better determined by the percent decrease in total cholesterol levels than by the absolute cholesterol level, say Japanese researchers.

        A team from the department of cardiology at Tokyo's Juntendo University School of Medicine investigated the relationship between decreased serum lipid levels during the therapy with pravastatin and changes in coronary angiography parameters among 265 patients with coronary atherosclerosis.

        The predominantly male participants aged between 18 and 75 years were noted to have 25% stenosis of one or more coronary arteries and a serum total cholesterol (TC) level of 200 mg/dL or greater (5.18 mM/I) and continued treatment with pravastatin for 3 years.

        Coronary angiography was performed before and 3 years after commencing the statin therapy to assess the relationship between mean segment diameter (MSD), minimal lumen diameter (MLD) and yearly changes in percent stenosis and TC levels.

        Subsequently 129 of the initial participant patients were followed for an average of 35 months. Only 68 patients underwent second angiograms, therefore this group was used for analysis.

        Researchers noted that during pravastatin therapy, the TC level decreased significantly from 239 mg/dL (6.19mM/l) to 210 mg/dL (5.44 mM/l), a 12% reduction (P<0.001). There was also a 5% increase in HDL-cholesterol although there was no significant change in triglyceride level (P=0.007).

        During follow-up, researchers noted a significant improvement in both MSD and MLD, which increased from 2.67mm to 2.76 mm and from 2.09 mm to 2.13 mm respectively, although they did not observe any changes in percent stenosis.

        There was also no correlation during treatment in the mean TC level and changes of angiography parameters, but a significant correlation was seen between the percent reduction of TC and the annual changes of MSD (R=-0.272, P=0.027). Furthermore a similar relationship was noted between the changes of MLD and percent reduction of TC (R=-0.260, P=0.035).
        Journal of Atheroscler Thrombosis 2003;10:1:25-31. "Preventing angiographic progression of coronary atherosclerosis with pravastatin"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send